<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116409</article-id><article-id pub-id-type="publisher-id">ACM-43440</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_39407410.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  苯磺酸左旋氨氯地平片治疗高血压临床疗效分析
  Analysis of Clinical Therapeutic Effect of Levamlodipine Besylate Tablets on Hypertension
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>牟</surname><given-names>俊宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>莉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>毕</surname><given-names>晓磊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>一兵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛市市立医院心内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2819</fpage><lpage>2824</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：对比分析高血压患者临床治疗中苯磺酸左旋氨氯地平片应用效果及安全性影响。方法：入选为2017年5月~2019年2月期间于本院以高血压为主诉就诊患者，共86例设为研究对象，开展临床对比研究，按照随机数字抽选法将入选人群随机分为对照组与研究组，各组样本容量均为43例。对照组接受苯磺酸氨氯地平片 + 缬沙坦治疗方案，研究组接受苯磺酸左旋氨氯地平片 + 缬沙坦治疗方案。对比两组治疗前后血压、心率、血管舒缩功能指标、血管内皮损伤相关因子，总有效率及药物毒副反应发生率。结果：入院时经临床检查，两组血压、心率、血流动力学指标、生化指标数据组间对比无明显差异，P &gt; 0.05；经临床治疗后，相较同期对照组，研究组血压、心率、血流舒缩功能指标、血管内皮损伤相关因子较对照组均获得显著改善，P &lt; 0.05；两组患者服药后均得到有效降压，且研究组降压总有效率较对照组具有一定优势，但对比无明显统计学差异，P &gt; 0.05；研究组治疗期间药物毒副反应率明显低于对照组，P &lt; 0.05。结论：苯磺酸左旋氨氯地平片在高血压临床治疗中的应用，可对患者实现有效降压，改善血管内皮功能，减少血管内皮损害，且安全性较高，临床应用价值显著。
   Objective: To compare and analyze the application effect and safety effect of levamlodipine besylate tablets in clinical treatment of hypertension. Methods: A total of 86 patients with hypertension as the chief complaint in our hospital from May 2017 to February 2019 were randomly selected as research subjects to carry out clinical comparative study. They were divided into the control group and the research group according to the results of random number selection method. The sample size of each group was 43 cases. The control group received amlodipine besylate tablets + valsartan treatment scheme, while the study group received levamlodipine besylate tablets + valsartan treatment scheme. The changes of blood pressure, heart rate, vascular endothelial function index, biochemical index data, therapeutic effect and incidence of drug toxicity and side effects were compared between the two groups before and after treatment. Results: After clinical examination on admission, there was no significant difference in blood pressure, heart rate, hemodynamic index and biochemical index between the two groups, P &gt; 0.05. After clinical treatment, compared with the control group at the same time, the blood pressure, heart rate, hemodynamic index and biochemical index data in the study group were significantly improved compared with the control group, P &lt; 0.05. Both groups of patients received effective treatment after taking the medicine, and the treatment effect of the study group has certain advantages over the control group, but there is no obvious difference between the two groups, P &gt; 0.05; the adverse drug reaction rate of the study group during treatment was significantly lower than that of the control group, P &lt; 0.05. Conclusion: The application of levamlodipine besylate tablets in the clinical treatment of hypertension can effectively relieve the symptoms of patients, improve vascular endothelial function and reduce hemodynamic damage, with high safety and significant clinical application value.
 
</p></abstract><kwd-group><kwd>苯磺酸左旋氨氯地平片，高血压，血管内皮功能，血流动力学，应用效果，安全性, Levamlodipine Besylate Tablets</kwd><kwd> Hypertension</kwd><kwd> Vascular Endothelial Function</kwd><kwd> Hemodynamics</kwd><kwd> Application Effect</kwd><kwd> Safety</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：对比分析高血压患者临床治疗中苯磺酸左旋氨氯地平片应用效果及安全性影响。方法：入选为2017年5月~2019年2月期间于本院以高血压为主诉就诊患者，共86例设为研究对象，开展临床对比研究，按照随机数字抽选法将入选人群随机分为对照组与研究组，各组样本容量均为43例。对照组接受苯磺酸氨氯地平片 + 缬沙坦治疗方案，研究组接受苯磺酸左旋氨氯地平片 + 缬沙坦治疗方案。对比两组治疗前后血压、心率、血管舒缩功能指标、血管内皮损伤相关因子，总有效率及药物毒副反应发生率。结果：入院时经临床检查，两组血压、心率、血流动力学指标、生化指标数据组间对比无明显差异，P &gt; 0.05；经临床治疗后，相较同期对照组，研究组血压、心率、血流舒缩功能指标、血管内皮损伤相关因子较对照组均获得显著改善，P &lt; 0.05；两组患者服药后均得到有效降压，且研究组降压总有效率较对照组具有一定优势，但对比无明显统计学差异，P &gt; 0.05；研究组治疗期间药物毒副反应率明显低于对照组，P &lt; 0.05。结论：苯磺酸左旋氨氯地平片在高血压临床治疗中的应用，可对患者实现有效降压，改善血管内皮功能，减少血管内皮损害，且安全性较高，临床应用价值显著。</p></sec><sec id="s2"><title>关键词</title><p>苯磺酸左旋氨氯地平片，高血压，血管内皮功能，血流动力学，应用效果，安全性</p></sec><sec id="s3"><title>Analysis of Clinical Therapeutic Effect of Levamlodipine Besylate Tablets on Hypertension<sup> </sup></title><p>Junyu Mu, Li Xu, Xiaolei Bi, Yibing Shao<sup>*</sup></p><p>Department of Cardiology, Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/51-1572342x5_hanspub.png" /></p><p>Received: May 21<sup>st</sup>, 2021; accepted: Jun. 9<sup>th</sup>, 2021; published: Jun. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/51-1572342x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To compare and analyze the application effect and safety effect of levamlodipine besylate tablets in clinical treatment of hypertension. Methods: A total of 86 patients with hypertension as the chief complaint in our hospital from May 2017 to February 2019 were randomly selected as research subjects to carry out clinical comparative study. They were divided into the control group and the research group according to the results of random number selection method. The sample size of each group was 43 cases. The control group received amlodipine besylate tablets + valsartan treatment scheme, while the study group received levamlodipine besylate tablets + valsartan treatment scheme. The changes of blood pressure, heart rate, vascular endothelial function index, biochemical index data, therapeutic effect and incidence of drug toxicity and side effects were compared between the two groups before and after treatment. Results: After clinical examination on admission, there was no significant difference in blood pressure, heart rate, hemodynamic index and biochemical index between the two groups, P &gt; 0.05. After clinical treatment, compared with the control group at the same time, the blood pressure, heart rate, hemodynamic index and biochemical index data in the study group were significantly improved compared with the control group, P &lt; 0.05. Both groups of patients received effective treatment after taking the medicine, and the treatment effect of the study group has certain advantages over the control group, but there is no obvious difference between the two groups, P &gt; 0.05; the adverse drug reaction rate of the study group during treatment was significantly lower than that of the control group, P &lt; 0.05. Conclusion: The application of levamlodipine besylate tablets in the clinical treatment of hypertension can effectively relieve the symptoms of patients, improve vascular endothelial function and reduce hemodynamic damage, with high safety and significant clinical application value.</p><p>Keywords:Levamlodipine Besylate Tablets, Hypertension, Vascular Endothelial Function, Hemodynamics, Application Effect, Safety</p><disp-formula id="hanspub.43440-formula50"><graphic xlink:href="//html.hanspub.org/file/51-1572342x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/51-1572342x8_hanspub.png" /> <img src="//html.hanspub.org/file/51-1572342x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>高血压是一类以体循环动脉血压异常升高为主要体征的临床常见慢性基础疾病，高血压造成的血管内皮功能损伤可诱发各类心脑血管疾病或肾脏疾病，需通过积极降压降低患者严重并发症风险 [<xref ref-type="bibr" rid="hanspub.43440-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref3">3</xref>]。目前对于高血压的控制性治疗主要借助药物手段实现，且随着制药技术的不断发展，高血压药物治疗方案多种多样 [<xref ref-type="bibr" rid="hanspub.43440-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref5">5</xref>]。苯磺酸氨氯地平既往研究表明其降压的有效性和安全性，本研究拟对比分析高血压临床治疗中苯磺酸左旋氨氯地平片应用效果及安全性影响，特开展本次研究，现将报告详述。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>随机选取2017年5月~2019年2月期间于本院以高血压为主诉就诊患者共86例设为研究对象开展临床对比研究，按照随机数字抽选法分组结果将其分为对照组与研究组，各组样本容量均为43例。</p><p>对照组，男/女，23/20例，年龄区间范围48~82岁，平均年龄(65.04 &#177; 4.29)岁；病程1.4~7.8年，平均(4.63 &#177; 0.57)年，其中1级/2级/3级高血压，15/22/6例。研究组，男/女，22/21例，年龄区间范围47~82岁，平均年龄(64.53 &#177; 4.07)岁；病程1.3~7.8年，平均(4.55 &#177; 0.48)年，其中1级/2级/3级高血压，14/24/5例。研究获本院伦理委员会批准后实施，经对比两组一般资料后结果无明显差异，即P &gt; 0.05，研究结果具有可比性。</p><p>纳入标准：患者入院后经临床查体后均确诊，且符合《中国高血压基层管理指南(2014年修订版)》中高血压相关诊断及分级标准 [<xref ref-type="bibr" rid="hanspub.43440-ref6">6</xref>]；患者及家属均在了解本次治疗研究细则后确认参与研究，签署《知情书》。排除标准：排除病理性高血压者；排除合并严重原发性心脑血管疾病者；排除研究期间自愿脱离者；排除合并严重肝肾功能损伤者。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>对照组接受苯磺酸氨氯地平片 + 缬沙坦治疗方案：1) 苯磺酸氨氯地平片(浙江京新药业股份有限公司，国药准字H20103356，5 mg/片)口服，起始剂量为5 mg/日，期间可根据患者治疗情况按2.5 mg/周剂量标准增加服药量，最大剂量为10 mg/日；2) 缬沙坦胶囊(北京诺华制药有限公司，国药准字H20040217，80 mg/粒)口服，1~2粒/日。</p><p>研究组接受苯磺酸左旋氨氯地平片 + 缬沙坦治疗方案：1) 苯磺酸左旋氨氯地平片(浙江昂利康制药股份有限公司，国药准字H20083460，2.5 mg/片)口服，初始剂量为2.5 mg/日，期间可根据患者治疗效果及药物反应，增加剂量至5 mg/日。2) 缬沙坦治疗剂型及方式同上。</p><p>两组患者均需连续治疗8周，治疗期间需积极改善生活行为，进行体重管理，限制钠盐摄入等，并养成血压自检及定期复诊的良好习惯。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>对比两组治疗前后血压、心率、血管内皮功能指标、生化指标数据变化，治疗效果及药物毒副反应发生率。</p><p>血管舒缩功能指标包括血管舒张功能及指尖脉搏容积。血管舒张功能采用彩色多普勒超声检查，患者取仰卧位后，将超声探头置于其肘窝处对其肱动脉进行纵向及横向扫查，先探查心脏舒张末期血管内径，15 min后待血管形态复常后，含服硝酸甘油5 min后，检测血管内径后，对血管舒张功能进行测算。指尖脉搏容积采用血管内皮功能检测仪检测。</p><p>血管内皮损伤相关因子包括血NO及ET-1，于患者就诊当日及治疗结束后次日，取晨间空腹静脉血3 ml后，分别采用ELISA法及放射免疫法进行检验。</p><p>疗效判定指标：显效：经治疗后，患者血压数值较治疗前改善幅度 &gt; 40%，且无线趋近复常，基本稳定；有效：患者血压数值较治疗前改善幅度在20%~40%内，且基本稳定；无效：未达到上述治疗指标者，且药物毒副反应明显 [<xref ref-type="bibr" rid="hanspub.43440-ref7">7</xref>]。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>研究所的各项数据中，血压、心率、血管内皮功能指标及生化指标均为连续型变量资料，用( x &#175; &#177; s )表示，t检验，治疗效果及药物毒副反应发生率均为定性资料，用(n, %)表示，x<sup>2</sup>检验，且数据均由SPSS23.0统计学软件统计分析，结果P &lt; 0.05且差异显著时，则具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者血压、心率指标对比</title><p>入院时经临床检查，两组血压、心率指标数据组间对比无明显差异，P &gt; 0.05；经临床治疗后，相较同期对照组，研究组血压、心率指标数据较对照组均获得显著改善，P &lt; 0.05。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of blood pressure and heart rate indicators ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >时间</th><th align="center" valign="middle"  rowspan="2"  >心率(次/分钟)</th><th align="center" valign="middle"  colspan="2"  >血压(mmHg)</th></tr></thead><tr><td align="center" valign="middle" >SBP</td><td align="center" valign="middle" >DBP</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >78.24 &#177; 8.53</td><td align="center" valign="middle" >165.42 &#177; 8.91</td><td align="center" valign="middle" >96.72 &#177; 7.41</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >74.61 &#177; 5.14</td><td align="center" valign="middle" >142.16 &#177; 4.32</td><td align="center" valign="middle" >87.64 &#177; 4.22</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >研究组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >78.47 &#177; 8.49</td><td align="center" valign="middle" >165.07 &#177; 9.24</td><td align="center" valign="middle" >96.55 &#177; 7.36</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >70.05 &#177; 4.89</td><td align="center" valign="middle" >131.43 &#177; 4.26</td><td align="center" valign="middle" >82.08 &#177; 4.13</td></tr><tr><td align="center" valign="middle" >t后</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >4.2148</td><td align="center" valign="middle" >11.5971</td><td align="center" valign="middle" >6.1746</td></tr><tr><td align="center" valign="middle" >P后</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >0.0001</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >0.0000</td></tr></tbody></table></table-wrap><p>表1. 血压、心率指标对比( x &#175; &#177; s )</p></sec><sec id="s7_2"><title>3.2. 两组患者血管内皮功能指标、生化指标对比</title><p>入院时两组血流动力学指标、生化指标数据对比无显著性差异，P &gt; 0.05；经临床治疗后，相较同期对照组，研究组血流动力学指标、生化指标数据较对照组均获得显著改善，P &lt; 0.05。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of vascular endothelial function indicators and biochemical indicators ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >时间</th><th align="center" valign="middle"  colspan="2"  >血管内皮功能指标</th><th align="center" valign="middle"  colspan="2"  >生化指标</th></tr></thead><tr><td align="center" valign="middle" >PAV (m/s)</td><td align="center" valign="middle" >FMD (%)</td><td align="center" valign="middle" >ET-1 (ng/L)</td><td align="center" valign="middle" >NO (μmol/L)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >0.85 &#177; 0.17</td><td align="center" valign="middle" >5.43 &#177; 1.62</td><td align="center" valign="middle" >70.53 &#177; 24.36</td><td align="center" valign="middle" >51.02 &#177; 15.73</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.06 &#177; 0.23</td><td align="center" valign="middle" >6.87 &#177; 2.02</td><td align="center" valign="middle" >64.31 &#177; 14.72</td><td align="center" valign="middle" >58.92 &#177; 16.78</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >研究组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >0.84 &#177; 0.19</td><td align="center" valign="middle" >5.47 &#177; 1.57</td><td align="center" valign="middle" >70.28 &#177; 23.89</td><td align="center" valign="middle" >51.23 &#177; 15.98</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.29 &#177; 0.25</td><td align="center" valign="middle" >7.86 &#177; 2.27</td><td align="center" valign="middle" >52.87 &#177; 15.46</td><td align="center" valign="middle" >71.24 &#177; 23.54</td></tr><tr><td align="center" valign="middle" >t后</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >4.4398</td><td align="center" valign="middle" >2.1364</td><td align="center" valign="middle" >3.5142</td><td align="center" valign="middle" >2.7946</td></tr><tr><td align="center" valign="middle" >P后</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >0.0356</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >0.0064</td></tr></tbody></table></table-wrap><p>表2. 血管内皮功能指标、生化指标对比( x &#175; &#177; s )</p></sec><sec id="s7_3"><title>3.3. 两组患者总有效率对比</title><p>两组患者服药后均得到有效治疗，且研究组治疗效果较对照组具有一定优势，但对比无明显差异，P &gt; 0.05。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of therapeutic effects (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >88.37 (38/43)</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >95.35 (41/43)</td></tr><tr><td align="center" valign="middle" >x<sup>2</sup></td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >1.3996</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >0.2368</td></tr></tbody></table></table-wrap><p>表3. 疗效对比(n, %)</p></sec><sec id="s7_4"><title>3.4. 两组患者毒副反应发生率对比</title><p>研究组治疗期间药物毒副反应率明显低于对照组，P &lt; 0.05。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of the incidence of toxic and side effects (n, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >头痛</th><th align="center" valign="middle" >水肿</th><th align="center" valign="middle" >胸痛</th><th align="center" valign="middle" >乏力</th><th align="center" valign="middle" >总发生率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >25.58 (11/43)</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6.98 (3/43)</td></tr><tr><td align="center" valign="middle" >x<sup>2</sup></td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >5.4603</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" >0.0194</td></tr></tbody></table></table-wrap><p>表4. 毒副反应发生率对比(n, %)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>高血压作为临床治疗中较为常见的慢性非传染性基础疾病，致病诱因复杂，且无法根治，而随着对高血压疾病临床研究的深入，大量研究数据表明 [<xref ref-type="bibr" rid="hanspub.43440-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref10">10</xref>]，血管内皮舒张性功能障碍是引发高血压的一类主要诱因，且随着高血压所致血流动力学指标异常的加剧，可逐渐增加对患者血管内皮功能损伤影响，从而与高血压病情相互影响，相互加剧，导致患者严重心脑血管疾病风险性不断加剧，故需及时予以患者针对性治疗，通过对其血流动力学指标及血管内皮功能的改善，逐渐降低疾病影响。</p><p>研究结果表明：入院时经临床检查，两组血压、心率、血流动力学指标、生化指标数据组间对比无明显差异，P &gt; 0.05；经临床治疗后，相较同期对照组，研究组血压、心率、血流动力学指标、生化指标数据较对照组均获得显著改善，P &lt; 0.05；两组患者服药后均得到有效治疗，且研究组治疗效果较对照组具有一定优势，但对比无明显差异，P &gt; 0.05；研究组治疗期间药物毒副反应率明显低于对照组，P &lt; 0.05。分析原因：苯磺酸氨氯地平是临床中较为常用的高血压治疗药物，其主要成分为具有慢通道阻滞作用的二氢吡啶类钙拮抗剂，药物成分在进入人体后可经钙离子通道，进入心脏平滑肌及心肌细胞内，实现对上述细胞中钙离子的选择性抑制，从而起到舒张心内血管及心肌的作用，增加血管内血流容积，从而起到改善患者血压，降低血管内皮损伤的作用 [<xref ref-type="bibr" rid="hanspub.43440-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref12">12</xref>]，在临床中多与肾素血管紧张素醛固酮系统激活剂(缬沙坦)类药物联合应用，借助其药物所含有的血管紧张素与心脏组织内各种组织细胞膜上特异受体结合，直接或间接作用于血压调节机制，从而实现苯磺酸氨氯地平治疗效果的辅助提升，有效缓解患者病情 [<xref ref-type="bibr" rid="hanspub.43440-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref14">14</xref>]。但随着高血压疾病治疗研究的深入，有学者 [<xref ref-type="bibr" rid="hanspub.43440-ref15">15</xref>] 指出苯磺酸氨氯地平对于原发性高血压岁具有良好治疗效果，但其中所含有的左旋体及右旋体成分中，对于心脑血管功能保护主要发挥作用的是左旋体成分，使得苯磺酸左旋氨氯地平药物便在现有制药基础上，从苯磺酸氨氯地平中所拆分出来，故在临床实际治疗应用中，苯磺酸左旋氨氯地平的应用，则可在苯磺酸氨氯地平类药物原有的心脑血管功能改善的基础上加强对心血管功能的有效保护，使患者血管内皮功能得到有效保护及提升，进而使血管舒张效果得到有效提升，增强血流动力学指标改善情况 [<xref ref-type="bibr" rid="hanspub.43440-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.43440-ref17">17</xref>]，在缬沙坦药物作用辅助下，进一步实现对患者病情的有效改善。在实际研究中指出苯磺酸氨氯地平片在进入人体后需经肝脏进行广泛性代谢，其中10%药物成分以原药形式排出体外，剩余60%部分则需在人体代谢后经尿液排出，终末消除半衰期时间较长，故药物成分易在人体易积累，引发毒副反应，且药物用量较大，而苯磺酸左旋氨氯地平片在人体药代方式与苯磺酸氨氯地平片虽相同，但其服用剂量相对较低，且终末消除半衰期时间较短，故大部分成分可经人体代谢顺利排出，患者毒副反应情况相对较低。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，苯磺酸左旋氨氯地平片在高血压临床治疗中的应用，可实现对患者症状的有效缓解，改善血管内皮功能，减少血流动力学损害，且安全性较高，临床应用价值显著。</p></sec><sec id="s10"><title>文章引用</title><p>牟俊宇,徐 莉,毕晓磊,邵一兵. 苯磺酸左旋氨氯地平片治疗高血压临床疗效分析Analysis of Clinical Therapeutic Effect of Levamlodipine Besylate Tablets on Hypertension[J]. 临床医学进展, 2021, 11(06): 2819-2824. https://doi.org/10.12677/ACM.2021.116409</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43440-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">赵丽庆, 刘士俊, 甘标. 老年高血压患者血压昼夜节律变化分析[J]. 职业与健康, 2015(10): 1337-1339.</mixed-citation></ref><ref id="hanspub.43440-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李航, 董忠, 马爱娟, 等. 北京市 2014 年高血压患者不同血压控制措施及效果比较[J]. 中华流行病学杂志, 2016, 37(9): 1202-1206.</mixed-citation></ref><ref id="hanspub.43440-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王冰玉, 简伟研. 老年人高血压患病知晓和血压控制的社会决定因素研究[J]. 中国全科医学, 2015, 18(2): 152-156.</mixed-citation></ref><ref id="hanspub.43440-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">虞泽星, 陈倩. 我国社区高血压患者药物治疗现况综合分析[J]. 中国全科医学, 2016, 19(B12): 304-306.</mixed-citation></ref><ref id="hanspub.43440-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">董婷, 刘素珍, 李继平. 社区高血压管理病人药物降压治疗管理及血压达标的影响因素分析[J]. 护理研究: 下旬版, 2016, 30(4): 1445-1448.</mixed-citation></ref><ref id="hanspub.43440-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">隋辉, 王文. 《中国高血压基层管理指南》(2014年修订版)要点解读[J]. 临床荟萃, 2015, 30(7): 721-724.</mixed-citation></ref><ref id="hanspub.43440-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">陈珠英, 郭新峰, 阴慧娟, 等. 弱激光治疗高血压降压疗效的系统评价与 Meta 分析[J]. 中国循证心血管医学杂志, 2017, 9(12): 1427-1432.</mixed-citation></ref><ref id="hanspub.43440-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ter Maaten, J.M., Damman, K., Verhaar, M.C., et al. (2016) Connecting Heart Failure with Preserved Ejection Fraction and Renal Dysfunction: The Role of Endothelial Dysfunction and Inflammation. European Journal of Heart Failure, 18, 588-598. &lt;br&gt;https://doi.org/10.1002/ejhf.497</mixed-citation></ref><ref id="hanspub.43440-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Szelényi, Z., Fazakas, Á., Szénási, G., et al. (2015) Inflammation and Oxidative Stress Caused by Nitric Oxide Synthase Uncoupling Might Lead to Left Ventricular Diastolic and Systolic Dysfunction in Patients with Hypertension. Journal of Geriatric Cardiology, 12, 1-10.</mixed-citation></ref><ref id="hanspub.43440-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Guazzi, M. and Naeije, R. (2017) Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging clinical Perspectives. Journal of the American College of Cardiology, 69, 1718-1734.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2017.01.051</mixed-citation></ref><ref id="hanspub.43440-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">余广兰. 阿托伐他汀联合苯磺酸氨氯地平治疗冠心病合并脑梗死的临床效果[J]. 海南医学院学报, 2015, 21(1): 29-31.</mixed-citation></ref><ref id="hanspub.43440-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">陈慧敏, 许逸飞. 苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究[J]. 中国临床药理学杂志, 2016, 32(12): 1072-1074.</mixed-citation></ref><ref id="hanspub.43440-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">林涛, 耿睿. 厄贝沙坦联合苯磺酸氨氯地平治疗糖尿病合并高血压的临床研究[J]. 中国卫生标准管理, 2015, 6(4): 106.</mixed-citation></ref><ref id="hanspub.43440-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王贵鹏, 骆小梅. 厄贝沙坦联合小剂量利尿剂对老年单纯收缩期高血压患者的疗效及血清学指标影响[J]. 海南医学院学报, 2017, 23(1): 30-33.</mixed-citation></ref><ref id="hanspub.43440-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X. and Tian, W. (2019) Efficacy of Amlodipine Besylate and Valsartan for the Treatment of Mild to Moderate Hypertension. Medicine, 98, e16264. &lt;br&gt;https://doi.org/10.1097/MD.0000000000016264</mixed-citation></ref><ref id="hanspub.43440-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Elliott, W.J. and Bistrika, E.A. (2018) Perindopril Arginine and Amlodipine Besylate for Hypertension: A Safety Evaluation. Expert Opinion on Drug Safety, 17, 207-216. &lt;br&gt;https://doi.org/10.1080/14740338.2018.1397129</mixed-citation></ref><ref id="hanspub.43440-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Handa, T., Jhajra, S., Bhagat, S., et al. (2017) Molecular Insight into Atypical Instability Behavior of Fixed-Dose Combination Containing Amlodipine Besylate and Losartan Potassium. Journal of Pharmaceutical and Biomedical Analysis, 136, 66-80. &lt;br&gt;https://doi.org/10.1016/j.jpba.2016.12.035</mixed-citation></ref></ref-list></back></article>